Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.

scientific article

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2012.04.044
P932PMC publication ID3490194
P698PubMed publication ID22537984
P5875ResearchGate publication ID224854335

P50authorAnna WaldQ41122225
Kathryn M. EdwardsQ52577914
Patricia L WinokurQ56481179
Karen L KotloffQ63214788
Lisa A JacksonQ97556689
Diana L. NoahQ109940643
P2093author name stringEmmanuel B Walter
Mark Wolff
Wilbur H Chen
Pandemic H1N1 Vaccine Adult Study Group
P2860cites workEffectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communitiesQ28741469
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.Q30227381
Response to a monovalent 2009 influenza A (H1N1) vaccine.Q30380581
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.Q30383576
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial.Q30383579
An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.Q30384418
The development of vaccine viruses against pandemic A(H1N1) influenzaQ30398053
Safety of influenza A (H1N1) vaccine in postmarketing surveillance in ChinaQ30399259
H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink projectQ30404999
Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trialQ30406785
Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.Q30407057
Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in ItalyQ30407814
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International StandardQ30409734
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.Q33974507
Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010.Q34112980
Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010.Q34118789
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjectsQ34697810
Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccineQ34761957
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and olderQ38380921
A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly AdultsQ38499447
Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B virusesQ40205161
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010Q43152358
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccineQ44910890
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.Q55041754
Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly PersonsQ56459658
P433issue28
P407language of work or nameEnglishQ1860
P921main subjectemergency managementQ1460420
pandemicQ12184
pandemic preparednessQ88434121
P304page(s)4240-4248
P577publication date2012-04-23
P1433published inVaccineQ7907941
P1476titlePhase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.
P478volume30

Reverse relations

cites work (P2860)
Q91941716Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females
Q30357144Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine.
Q30366806Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.
Q30362185Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.
Q30352081Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults.
Q30378668Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults
Q49587964Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults
Q30369098Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations
Q30204573Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial
Q30371419Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old
Q58566464Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam
Q30204578Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant

Search more.